Maprotiline

Last updated
Maprotiline
Maprotiline structure.svg
Maprotiline ball-and-stick model.png
Clinical data
Trade names Ludiomil, others
Other namesMaprotiline hydrochloride; Maprotiline methanesulfonate; Ba 34276 [1] [2] [3]
AHFS/Drugs.com Monograph
MedlinePlus a682158
Routes of
administration
Oral, intramuscular, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 66–70%
Protein binding 88%
Metabolism hepatic
Onset of action 6 hours
Elimination half-life 27–58 hours
Excretion Urine (57%) and bile (30%) as glucuronides, 3–4% as unchanged drug
Identifiers
  • N-Methyl-9,10-ethanoanthracene-9(10H)-propanamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.030.532 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C20H23N
Molar mass 277.411 g·mol−1
3D model (JSmol)
  • CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12
  • InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3/t15-,20+ X mark.svgN
  • Key:QSLMDECMDJKHMQ-GSXCWMCISA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Maprotiline, sold under the brand name Ludiomil among others, is a tetracyclic antidepressant (TeCA) that is used in the treatment of depression. [5] It may alternatively be classified as a tricyclic antidepressant (TCA), specifically a secondary amine. [5] In terms of its chemistry and pharmacology, maprotiline is closely related to such-other secondary-amine TCAs as nortriptyline and protriptyline and has similar effects to them, [6] [5] albeit with more distinct anxiolytic effects. [7] [8] [9] Additionally, whereas protriptyline tends to be somewhat more stimulating and in any case is distinctly more-or-less non-sedating, [10] mild degrees of sedation may be experienced with maprotiline. [11]

Contents

Medical uses

Maprotiline is used in the treatment of depression, such as depression associated with agitation or anxiety and has similar efficacy to the antidepressant drug moclobemide. [12] This finding has also been validated by a group of general practitioners who compared the respective efficacy and tolerability of maprotiline and moclobemide. [13]

The use of maprotiline in the treatment of enuresis in pediatric patients has so far not been systematically explored and its use is not recommended. [15] Safety and effectiveness in the pediatric population in general have not been established. Anyone considering the use of maprotiline in a child or adolescent must balance the potential risks with the clinical need.

A very small body of research has also explored the potential of maprotiline in treating diabetic kidney disease [16] and it has been measured against amitriptyline in this regard. [17]

Maprotiline and fluoxetine have also been found, among certain lines of research, to have quite potent anti-profilerative effects against certain forms of cancer of the Burkitt lymphoma type. [18] [19] One study also bore ought a certain level of evidence regarding maprotiline’s ability to suppress both cholesterol biosynthesis and hepatocellular carcinoma liver-cancer progression.

Maprotiline was also measured against imipramine, fluoxetine and ketamine in an experiment-model involving two different kinds of chicken differently-conditioned against stress, including (black) Australorps in the proposed treatment of treatment-resistant depression in humans. [20]

In general, lower dosages are recommended for patients over 60 years of age. Dosages of 50 mg to 75 mg daily are usually satisfactory as maintenance therapy for elderly patients who do not tolerate higher amounts. [21] [22] In any case, 225 m.g./d. is the absolute-maximum highest recommended dose for this drug, as any more can predispose more significantly to seizures. 150 m.g. is the average optimal daily dose for otherwise-healthy patients who can tolerate a full dose.

Available forms

Contraindications

In generalised theory, maprotiline (as with other tricyclic antidepressants, besides trimipramine [23] [24] [25] and possibly clomipramine) may somewhat worsen certain features of schizophrenia, necessitating caution in prescribing them to someone with it and continuation of the antipsychotic treatment (e.g., with risperidone or olanzapine). However, certain bodies of evidence have found maprotiline a useful augment in treating some of the negative, or "anaesthetic", symptoms of schizophrenia and in probable extension pronounced schizoidia (including the characteristic deterioration in personal grooming/appearance). [26] [27] It has also been weighed against fluvoxamine in this overall regard (i.e., treating the negative symptoms of schizophrenia), [28] with fluvoxamine evidencing clear superiority therein. Maprotiline, however, may be specifically useful for the "negative symptom" of alogia (poverty of thought and/or speech) and in this regard was found demonstrably superior to the other control-drugs (alprazolam, bromocriptine, citalopram, fluoxetine, fluvoxamine, nortriptyline) in one study. [29] Citalopram, clomipramine and fluvoxamine appeared particularly useful in the study for reducing affective blunting, with alprazolam (Xanax) and maprotiline ranking joint-next.

Patients with bipolar affective disorder should not receive antidepressants whilst in a manic phase (including hypomania) under any circumstances whatsoever. (By the same analogy, people with schizoaffective disorder, bipolar type should not be taking maprotiline or other antidepressants while manic.) This is because antidepressants are known to come with the risk of worsening acute mania or precipitating it in so vulnerably-predisposed people. [30] [31]

They (antidepressants) may also negatively interfere with the treatment of mixed bipolar states (pure or schizo-affective), where electro-convulsive therapy [32] [33] (generally bilateral), valproate [34] and antipsychotics prove more beneficial (lithium should not be administered concurrently with E.C.T. treatment, as it may induce severe confusion [35] ). [36] However, maprotiline (at a high dose) was put to good use in one particular case, of one young man presenting with what was very-possibly a mixed-manic episode with a heavy preponderance of depressive symptoms (appearing as depression with significant narcissistic traits; including extrapunitive tendencies/blame-shifting, entitlement and interpersonal exploitation; and provisionally considered narcissistic depression). [37] The maprotiline was combined with mirtazapine (low-dose), sodium valproate and aripiprazole.

Absolute

Special caution needed

Suicidal patients

As with other antidepressants, maprotiline increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of maprotiline or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Maprotiline is not approved for use in pediatric patients. [39]

Pregnancy and lactation

Reproduction studies have been performed in female laboratory rabbits, mice, and rats at doses up to 1.3, 7, and 9 times the maximum daily human dose respectively and have revealed no evidence of impaired fertility or harm to the fetus due to maprotiline. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Maprotiline is excreted in breast milk. At steady-state, the concentrations in milk correspond closely to the concentrations in whole blood. Caution should be exercised when maprotiline hydrochloride is administered to a nursing woman.

Side effects

The side-effect profile is comparable to other TCAs and TeCAS and many of the following are due to anticholinergic (which are less prominent than those of most TCAs) and antihistamine effects. [15] Most often seen are:

Maprotiline causes a strong initial sedation (first 2 to 3 weeks of therapy) and is therefore indicated to treat agitated patients or those with suicidal risks. It causes anticholinergic side effects (dry mouth, constipation, urinary hesitancy, etc.) with much lower incidence than amitriptyline. Originally, the manufacturer claimed that maprotiline is better tolerated than other TCAs and TeCAs. However, seizures, leukopenia and skin reactions occur more often with maprotiline than with comparable drugs (e.g., amitriptyline, protriptyline, mirtazapine). Indeed, seizures are greater risk for concern with maprotiline than with all other tricyclic antidepressants [40] (rising from 75 mg, becoming significant at daily doses ≥ 200 m.g.), including clomipramine. It should thus be prescribed with particular, if not extreme, caution to people with a history of epilepsy/seizures of any other kind. In any case, the total daily dose should be kept to ≤ 225 milligrams.

Maprotiline has no known potential for abuse and psychological dependence.

Withdrawal

Withdrawal symptoms frequently seen when treatment with maprotiline is stopped abruptly (agitation, anxiety, insomnia, sometimes activation of mania or rebound depression) can be avoided by reducing the daily dose of maprotiline gradually by approximately 25% each week. If treatment has to be stopped at once for medical reasons, the use of a benzodiazepine (e.g., lorazepam, clonazepam, diazepam) for a maximum of 4 weeks as needed will usually suppress withdrawal symptoms.

Interactions

Maprotiline does have a wide range of possible interactions. Some are typical for TCAs and TeCAs, others are caused by specific metabolic effects (e.g., high plasma-protein-binding) of maprotiline:

Increased drug actions:

Although concurrent administration of tricyclic antidepressants (likewise with SSRIs) and MAOIs has been considered particularly dangerous, even fatal, across various medical and pharmaceutical lines across the decades, the premise for this line of thinking, although commonly accepted, may be erroneous. Specialist-research into this [41] and practical clinical experience involving the co-administration of tricyclics and MAOIs have suggested that it is only tricyclics with strong specific serotonin-reuptake inhibitory action (clomipramine and, to a lesser extent, imipramine) that are dangerous to give in combination with MAOIs. Other antidepressants; which may or may not have a significant serotoninergic background otherwise but either way lack in particularly appreciable reuptake-inhibition therein specifically (e.g., mirtazapine, amitriptyline, trazodone, lofepramine, nortriptyline); may be safe to take alongside MAOIs, where the likes of venlafaxine, SSRIs and clomipramine are not. With maprotiline, this has been demonstrated to be the case with moclobemide, [42] a drug it is often compared and considered somewhat analogous (along certain lines) to, and, tentatively, brofaromine [43] (a research-agent MAOI which was never brought to full marketing development). Moclobemide specifically, however, may increase maprptiline plasma-levels [44] and may necessitate dose-modification(s).

In any case, however, it is very-strongly advised that an MAOI is added to the (compatible) tricyclic and not the other way around, as adding a tricyclic to an existing treatment-regime involving an MAOI may significantly increase the risk of going into hypertensive crisis.

Decreased drug actions:

Other types of interaction:

Pharmacology

Pharmacodynamics

Maprotiline [45]
SiteKi (nM)SpeciesRef
SERT Tooltip Serotonin transporter5,800Human [46]
NET Tooltip Norepinephrine transporter11–12Human [46] [47]
DAT Tooltip Dopamine transporter1,000Human [46]
5-HT2A 51Rat [48]
5-HT2C 122Rat [48]
5-HT6 NDNDND
5-HT7 50Guinea pig [49]
α1 90Human [50]
α2 9,400Human [50]
D1 402Human [51]
D2 350–665Human [51] [50]
D3 504Human [51]
D4 NDNDND
D5 429Human [51]
H1 0.79–2.0Human [52] [51] [53] [50]
H2 776Human [52]
H3 66,100Human [51]
H4 85,100Human [52]
mACh Tooltip Muscarinic acetylcholine receptor570Human [54] [50]
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.

Maprotiline exhibits strong effects as a norepinephrine reuptake inhibitor with only weak actions the reuptake of serotonin and dopamine. [55] [15] It is also a strong antagonist of the H1 receptor, a moderate antagonist of the 5-HT2 and α1-adrenergic receptors, and a weak antagonist of the D2 and muscarinic acetylcholine receptors. Maprotiline has also more recently been identified as a potent antagonist of the 5-HT7 receptor, with this action potentially playing an important role in its antidepressant effectiveness. [56] The drug is a strong antihistamine, but unlike most TCAs, has minimal anticholinergic effects. [57]

The pharmacological profile of maprotiline explains its antidepressant, sedative, anxiolytic, and sympathomimetic activities. In accordance to the pharmacological characteristics it is used in the treatment of depression, such as depression associated with agitation or anxiety. Additionally, it shows strong antagonism against reserpine-induced effects in animal studies, as do the other 'classical' antidepressants. Although maprotiline behaves in most regards as a 'first-generation antidepressant' it is commonly referred to as 'second-generation antidepressant'.

The postulated mechanism of maprotiline is that it acts primarily by potentiation of central adrenergic synapses by blocking reuptake of norepinephrine at nerve endings. This pharmacological action is thought to be primarily responsible for the drug's antidepressant and anxiolytic effects. It is a strong norepinephrine reuptake inhibitor with only weak effects on serotonin and dopamine reuptake. At higher doses, however, maprotiline increases serotonergic transmission and increases the level of serotonin available. [58]

Pharmacokinetics

After oral use absorption is good. It binds to plasma proteins 80–90%. Maximal plasma concentration is reached 6 hours after use. The mean time to peak is 12 hours. The terminal half-life of averages 51 hours.

Chemistry

An alternative structural representation of the central ring of maprotiline. Maprotiline Formula V.1.svg
An alternative structural representation of the central ring of maprotiline.
A 3D representation of the structure of maprotiline. Notice the bridge in the central ring. Maprotiline3Dan.gif
A 3D representation of the structure of maprotiline. Notice the bridge in the central ring.

Maprotiline is a tetracyclic compound and is grouped with the TeCAs. [6] [5] Its chemical name is N-methyl-9,10-ethanoanthracen-9(10H)-propylamine. [59] The drug has a dibenzobicyclo[2.2.2]octadiene (9,10-dihydro-9,10-ethanoanthracene) ring system; that is, a tricyclic anthracene ring system with an ethylene bridge across the central ring. [6] [5] This results in it having a unique three-dimensional central ring (a bicyclo[2.2.2]octane or 1,4-endoethylenecyclohexane ring) and being a tetracyclic rather than a tricyclic compound. [6] However, it could also or alternatively be considered to be a tricyclic and hence a TCA. [5] In addition to its heterocyclic ring system, maprotiline has an alkyl amine side chain attached similarly to other TCAs (but notably unlike other TeCAs). [6] [5] In terms of the side chain, it is a secondary amine, [5] and its chemical structure, aside from the ethylene link in the central ring, is similar to that of secondary amine TCAs like nortriptyline and protriptyline. [6] [59] In accordance, the pharmacology of maprotiline is very similar to that of secondary amine TCAs. [6] [5]

Maprotiline is very similar in structure to the anxiolytic, sedative, and muscle relaxant drug benzoctamine (Tacitin). [6] [60] The only structural difference between the two compounds is in the length of their side chain. [6] [60] However, this modification results in considerable differences in their pharmacological and therapeutic effects. [6] [60]

History

Maprotiline was developed by Ciba (now operated by Novartis). [61] It was patented in 1966 and was first described in the literature in 1969. [61] The drug was introduced for medical use in 1974. [61] [62] Generics are now widely available. It was introduced after most of the other TCAs but was the first TeCA to be developed and marketed, with the TeCAs mianserin and amoxapine following shortly thereafter and mirtazapine being introduced later on. [61] [62]

Society and culture

Ludiomil (maprotiline) 25 mg tablets by Ciba-Geigy. Ludiomil25mg.jpg
Ludiomil (maprotiline) 25 mg tablets by Ciba-Geigy.

Generic names

Maprotiline is the English and French generic name of the drug and its INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name, BAN Tooltip British Approved Name, and DCF Tooltip Dénomination Commune Française, while maprotiline hydrochloride is its USAN Tooltip United States Adopted Name, USP Tooltip United States Pharmacopeia, BANM Tooltip British Approved Name and JAN Tooltip Japanese Accepted Name. [1] [2] [63] [3] Its generic name in Spanish and Italian and its DCIT Tooltip Denominazione Comune Italiana are maprotilina, in German is maprotilin, and in Latin is maprotilinum. [2] [3] The methanesulfonate (mesylate) salt is known unofficially as maprotiline methanesulfonate. [2] [3]

Brand names

Maprotiline is marketed throughout the world, mainly under the brand name Ludiomil. [2] [3] It is also available under a variety of other brand names including Deprilept, Maprolu, and Psymion among others. [2] [3]

Although it remains available across the world, it was discontinued in the United Kingdom in July 2006. Mylan, a key manufacturer of maprotiline in the United States, discontinued production in June 2021. [64]

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

An anxiolytic is a medication or other intervention that reduces anxiety. This effect is in contrast to anxiogenic agents which increase anxiety. Anxiolytic medications are used for the treatment of anxiety disorders and their related psychological and physical symptoms.

<span class="mw-page-title-main">Tricyclic antidepressant</span> Class of medications

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The effectiveness of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

<span class="mw-page-title-main">Fluvoxamine</span> SSRI antidepressant drug

Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is primarily used to treat major depressive disorder and obsessive–compulsive disorder (OCD), but is also used to treat anxiety disorders such as panic disorder, social anxiety disorder, and post-traumatic stress disorder.

<span class="mw-page-title-main">Amitriptyline</span> Tricyclic antidepressant

Amitriptyline, sold under the brand name Elavil among others, is a tricyclic antidepressant primarily used to treat major depressive disorder, a variety of pain syndromes such as neuropathic pain, fibromyalgia, migraine and tension headaches. Due to the frequency and prominence of side effects, amitriptyline is generally considered a second-line therapy for these indications.

<span class="mw-page-title-main">Serotonin–norepinephrine reuptake inhibitor</span> Class of antidepressant medication

Serotonin–norepinephrine reuptake inhibitors (SNRIs) are a class of antidepressant medications used to treat major depressive disorder (MDD), anxiety disorders, social phobia, chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. Off-label uses include treatments for attention-deficit hyperactivity disorder (ADHD), obsessive–compulsive disorder (OCD), and migraine prevention. SNRIs are monoamine reuptake inhibitors; specifically, they inhibit the reuptake of serotonin and norepinephrine. These neurotransmitters are thought to play an important role in mood regulation. SNRIs can be contrasted with the selective serotonin reuptake inhibitors (SSRIs) and norepinephrine reuptake inhibitors (NRIs), which act upon single neurotransmitters.

<span class="mw-page-title-main">Imipramine</span> Antidepressant

Imipramine, sold under the brand name Tofranil, among others, is a tricyclic antidepressant (TCA) mainly used in the treatment of depression. It is also effective in treating anxiety and panic disorder. Imipramine is taken by mouth.

<span class="mw-page-title-main">Clomipramine</span> Antidepressant

Clomipramine, sold under the brand name Anafranil among others, is a tricyclic antidepressant (TCA). It is used in the treatment of various conditions, most-notably obsessive–compulsive disorder but also many other disorders, including hyperacusis, panic disorder, major depressive disorder, trichotilomania, body dysmorphic disorder and chronic pain. It has also been notably used to treat premature ejaculation and the cataplexy associated with narcolepsy.

<span class="mw-page-title-main">Doxepin</span> Medication to treat depressive disorder, anxiety disorders, chronic hives, and trouble sleeping

Doxepin is a medication belonging to the tricyclic antidepressant (TCA) class of drugs used to treat major depressive disorder, anxiety disorders, chronic hives, and insomnia. For hives it is a less preferred alternative to antihistamines. It has a mild to moderate benefit for sleeping problems. It is used as a cream for itchiness due to atopic dermatitis or lichen simplex chronicus.

<span class="mw-page-title-main">Trimipramine</span> Antidepressant

Trimipramine, sold under the brand name Surmontil among others, is a tricyclic antidepressant (TCA) which is used to treat depression. It has also been used for its sedative, anxiolytic, and weak antipsychotic effects in the treatment of insomnia, anxiety disorders, and psychosis, respectively. The drug is described as an atypical or "second-generation" TCA because, unlike other TCAs, it seems to be a fairly weak monoamine reuptake inhibitor. Similarly to other TCAs, however, trimipramine does have antihistamine, antiserotonergic, antiadrenergic, antidopaminergic, and anticholinergic activities.

<span class="mw-page-title-main">Trazodone</span> Antidepressant medication

Trazodone, sold under many brand names, is an antidepressant medication. It is used to treat major depressive disorder, anxiety disorders, and insomnia. The medication is taken orally.

<span class="mw-page-title-main">Tianeptine</span> Atypical antidepressant

Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome.

<span class="mw-page-title-main">Moclobemide</span> Antidepressant

Moclobemide, sold under the brand names Amira, Aurorix, Clobemix, Depnil and Manerix among others, is a reversible inhibitor of monoamine oxidase A (RIMA) drug primarily used to treat depression and social anxiety. It is not approved for use in the United States, but is approved in other Western countries such as Canada, the UK and Australia. It is produced by affiliates of the Hoffmann–La Roche pharmaceutical company. Initially, Aurorix was also marketed by Roche in South Africa, but was withdrawn after its patent rights expired and Cipla Medpro's Depnil and Pharma Dynamic's Clorix became available at half the cost.

<span class="mw-page-title-main">Butriptyline</span> Atypical tricyclic antidepressant medication

Butriptyline, sold under the brand name Evadyne among others, is a tricyclic antidepressant (TCA) that has been used in the United Kingdom and several other European countries for the treatment of depression but appears to no longer be marketed. Along with trimipramine, iprindole, and amoxapine, it has been described as an "atypical" or "second-generation" TCA due to its relatively late introduction and atypical pharmacology. It was very little-used compared to other TCAs, with the number of prescriptions dispensed only in the thousands.

<span class="mw-page-title-main">Lofepramine</span> Chemical compound

Lofepramine, sold under the brand names Gamanil, Lomont, and Tymelyt among others, is a tricyclic antidepressant (TCA) which is used to treat depression. The TCAs are so named as they share the common property of having three rings in their chemical structure. Like most TCAs lofepramine is believed to work in relieving depression by increasing concentrations of the neurotransmitters norepinephrine and serotonin in the synapse, by inhibiting their reuptake. It is usually considered a third-generation TCA, as unlike the first- and second-generation TCAs it is relatively safe in overdose and has milder and less frequent side effects.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

Selective serotonin reuptake inhibitors, or serotonin-specific re-uptake inhibitor (SSRIs), are a class of chemical compounds that have application as antidepressants and in the treatment of depression and other psychiatric disorders. SSRIs are therapeutically useful in the treatment of panic disorder (PD), posttraumatic stress disorder (PTSD), social anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), and anorexia. There is also clinical evidence of the value of SSRIs in the treatment of the symptoms of schizophrenia and their ability to prevent cardiovascular diseases.

Selective norepinephrine reuptake inhibitors (sNRIs) are a class of drugs that have been marketed as antidepressants and are used for various mental disorders, mainly depression and attention-deficit hyperactivity disorder (ADHD). The norepinephrine transporter (NET) serves as the fundamental mechanism for the inactivation of noradrenergic signaling because of the NET termination in the reuptake of norepinephrine (NE). The selectivity and mechanism of action for the NRI drugs remain mostly unresolved and, to date, only a limited number of NRI-selective inhibitors are available. The first commercially available selective NRI was the drug reboxetine (Edronax), developed as a first-line therapy for major depressive disorder. Atomoxetine (Strattera) is another potent and selective NRI which is also effective and well tolerated for the treatment of ADHD in adults; it may also be a new treatment option for adults with ADHD, particularly for those patients at risk of substance abuse.

References

  1. 1 2 Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 752–. ISBN   978-1-4757-2085-3.
  2. 1 2 3 4 5 6 Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 630–. ISBN   978-3-88763-075-1.
  3. 1 2 3 4 5 6 "Maprotiline - Drugs.com". drugs.com. Retrieved 28 March 2018.
  4. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  5. 1 2 3 4 5 6 7 8 9 Williams DA (24 January 2012). "Antidepressants". In Lemke TL, Williams DA (eds.). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 591–. ISBN   978-1-60913-345-0.
  6. 1 2 3 4 5 6 7 8 9 10 Zhou Y (22 October 2013). "New Generation of Antidepressants: Maprotiline". Drugs in Psychiatric Practice. Elsevier. pp. 222–. ISBN   978-1-4831-9193-5.
  7. Guimarães FS, Zuardi AW, Graeff FG (January 1987). "Effect of chlorimipramine and maprotiline on experimental anxiety in humans". Journal of Psychopharmacology. 1 (3): 184–192. doi:10.1177/026988118700100305. PMID   22158980. S2CID   8444656.
  8. Vinader-Caerols C, Martos AJ, Monleón S, Arenas MC, Parra A (2006). "Acute effects of maprotiline on learning, anxiety, activity and analgesia in male and female mice". Acta Neurobiologiae Experimentalis. 66 (1): 23–31. doi: 10.55782/ane-2006-1584 . PMID   16617674.
  9. Pecknold JC, Familamiri P, McClure DJ, Elie R, Chang H (May 1985). "Trimipramine and maprotiline: antidepressant, anxiolytic, and cardiotoxic comparison". The Journal of Clinical Psychiatry. 46 (5): 166–171. PMID   2859273.
  10. Brownell LG, Perez-Padilla R, West P, Kryger MH (1983). "The role of protriptyline in obstructive sleep apnea". Bulletin Européen de Physiopathologie Respiratoire. 19 (6): 621–4. PMID   6360257.
  11. Holmberg G (May 1988). "Sedative effects of maprotiline and amitriptyline". Acta Psychiatrica Scandinavica. 77 (5): 584–6. doi:10.1111/j.1600-0447.1988.tb05171.x. PMID   3044007. S2CID   41977086.
  12. Delini-Stula A, Mikkelsen H, Angst J (October 1995). "Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies". Journal of Affective Disorders. 35 (1–2): 21–30. doi:10.1016/0165-0327(95)00034-K. PMID   8557884.
  13. Gachoud JP, Dick P, Köhler M (1994). "Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners". Clinical Neuropharmacology. 17 (Suppl 1): S29–37. doi:10.1097/00002826-199417001-00005. PMID   7954482. S2CID   260560762.
  14. Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH (December 1997). "A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics". The Clinical Journal of Pain. 13 (4): 313–23. doi:10.1097/00002508-199712000-00009. PMID   9430812.
  15. 1 2 3 "DRUGDEX Evaluations - Maprotiline" . Retrieved 25 April 2013.
  16. Zhou, Z. and Liu, S., 2022. Maprotiline Ameliorates High Glucose-Induced Dysfunction in Renal Glomerular Endothelial Cells. Experimental and Clinical Endocrinology & Diabetes, 130(09), pp.596-603.
  17. Singh R, Kishore L, Kaur N (February 2014). "Diabetic peripheral neuropathy: current perspective and future directions". Pharmacological Research. 80: 21–35. doi:10.1016/j.phrs.2013.12.005. PMID   24373831. S2CID   6097534.
  18. Cloonan SM, Drozgowska A, Fayne D, Williams DC (March 2010). "The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters". Leukemia & Lymphoma. 51 (3): 523–39. doi:10.3109/10428190903552112. PMID   20141432. S2CID   33104465.
  19. Cloonan SM, Williams DC (April 2011). "The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma". International Journal of Cancer. 128 (7): 1712–23. doi:10.1002/ijc.25477. PMID   20503272. S2CID   24955263.
  20. Sufka KJ, White SW (November 2013). "Identification of a treatment-resistant, ketamine-sensitive genetic line in the chick anxiety-depression model". Pharmacology, Biochemistry, and Behavior. 113: 63–7. doi:10.1016/j.pbb.2013.10.013. PMID   24157688. S2CID   23648185.
  21. "Maprotiline: MedlinePlus Drug Information". www.nlm.nih.gov. Retrieved 29 September 2013.
  22. "Maprotiline - FDA prescribing information, side effects and uses". www.drugs.com. Archived from the original on 30 December 2019. Retrieved 29 September 2013.
  23. Berger M, Gastpar M (1996). "Trimipramine: a challenge to current concepts on antidepressives". European Archives of Psychiatry and Clinical Neuroscience. 246 (5): 235–9. doi:10.1007/BF02190274. PMID   8863001. S2CID   29596291.
  24. Eikmeier G, Muszynski K, Berger M, Gastpar M (September 1990). "High-dose trimipramine in acute schizophrenia. Preliminary results of an open trial". Pharmacopsychiatry. 23 (5): 212–4. doi:10.1055/s-2007-1014510. PMID   1979173. S2CID   5719177.
  25. Eikmeier G, Berger M, Lodemann E, Muszynski K, Kaumeier S, Gastpar M (1991). "Trimipramine--an atypical neuroleptic?". International Clinical Psychopharmacology. 6 (3): 147–53. doi:10.1097/00004850-199100630-00003. PMID   1806621. S2CID   41564511.
  26. Yamagami S, Soejima K (1989). "Effect of maprotiline combined with conventional neuroleptics against negative symptoms of chronic schizophrenia". Drugs Under Experimental and Clinical Research. 15 (4): 171–6. PMID   2570687.
  27. Waehrens J, Gerlach J (May 1980). "Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo". Acta Psychiatrica Scandinavica. 61 (5): 438–44. doi:10.1111/j.1600-0447.1980.tb00882.x. PMID   6105762. S2CID   40809634.
  28. Silver H, Shmugliakov N (June 1998). "Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study". Journal of Clinical Psychopharmacology. 18 (3): 208–11. doi:10.1097/00004714-199806000-00005. PMID   9617979.
  29. Shafti SS, Rey A, Abad A (2005). "Drug – Specific Responsiveness of Negative Symptoms". International Journal of Psychosocial Rehabilitation. pp. 10 (1), 43–51. Archived from the original on 2012-07-12. Retrieved 2012-04-29.
  30. Benazzi F, Mazzoli M, Rossi E (July 1992). "Severe mania after maprotiline-induced coma". Pharmacopsychiatry. 25 (4): 207. doi:10.1055/s-2007-1014407. PMID   1528960. S2CID   260253520.
  31. Wehr TA, Goodwin FK (November 1987). "Can antidepressants cause mania and worsen the course of affective illness?". The American Journal of Psychiatry. 144 (11): 1403–11. doi:10.1176/ajp.144.11.1403. PMID   3314536.
  32. Perugi G, Medda P, Toni C, Mariani MG, Socci C, Mauri M (April 2017). "The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features". Current Neuropharmacology. 15 (3): 359–371. doi:10.2174/1570159X14666161017233642. PMC   5405614 . PMID   28503107.
  33. Kuzman MR, Medved V, Velagic V, Goluza E, Bradas Z (June 2012). "The use of electroconvulsive therapy to treat schizoaffective disorder in a patient with pacemaker: a case report". Psychiatria Danubina. 24 (2): 211–4. PMID   22706421.
  34. Azorin JM, Belzeaux R, Cermolacce M, Kaladjian A, Corréard N, Dassa D, Dubois M, Maurel M, Micoulaud Franchi JA, Pringuey D, Fakra E (December 2013). "[Recommendations for the treatment of mixed episodes in current guidelines]". L'Encephale (in French). 39 (Suppl 3): S185–7. doi:10.1016/S0013-7006(13)70120-9. PMID   24359859.
  35. Patel RS, Bachu A, Youssef NA (2020). "Combination of lithium and electroconvulsive therapy (ECT) is associated with higher odds of delirium and cognitive problems in a large national sample across the United States". Brain Stimulation. 13 (1): 15–19. doi: 10.1016/j.brs.2019.08.012 . PMID   31492631. S2CID   201125145.
  36. Krüger S, Trevor Young L, Bräunig P (June 2005). "Pharmacotherapy of bipolar mixed states". Bipolar Disorders. 7 (3): 205–15. doi:10.1111/j.1399-5618.2005.00197.x. PMID   15898959.
  37. Saito S, Kobayashi T, Kato S (2013). "[A case of major depressive disorder barely distinguishable from narcissistic personality disorder]". Seishin Shinkeigaku Zasshi = Psychiatria et Neurologia Japonica (in Japanese). 115 (4): 363–71. PMID   23789317.
  38. Simeon J, Maguire J, Lawrence S (1981). Maprotiline effects in children with enuresis and behavioural disorders. Progress in Neuro-Psychopharmacology 5 ( 5–6), 495–8
  39. U.S. National Library of Medicine. Last Reviewed 1 Sept. 2010 Medline Plus entry for Maprotiline
  40. Knudsen K, Heath A (February 1984). "Effects of self poisoning with maprotiline". British Medical Journal (Clinical Research Ed.). 288 (6417): 601–3. doi:10.1136/bmj.288.6417.601. PMC   1444313 . PMID   6421394.
  41. Gillman K (October 2017). ""Much ado about nothing": monoamine oxidase inhibitors, drug interactions, and dietary tyramine". CNS Spectrums. 22 (5): 385–387. doi: 10.1017/S1092852916000651 . PMID   28148312. S2CID   206312818.
  42. Laux G, Beckmann H, Classen W, Becker T (1989). "Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder". Journal of Neural Transmission. Supplementum. 28: 45–52. PMID   2677241.
  43. Hoencamp E, Haffmans PM, Dijken WA, Hoogduin CA, Nolen WA, van Dyck R (March 1994). "Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients". Journal of Affective Disorders. 30 (3): 219–27. doi:10.1016/0165-0327(94)90082-5. PMID   8006248.
  44. König F, Wolfersdorf M, Löble M, Wössner S, Hauger B (July 1997). "Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression". Pharmacopsychiatry. 30 (4): 125–7. doi:10.1055/s-2007-979497. PMID   9271778. S2CID   35570626.
  45. Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 7 May 2022.
  46. 1 2 3 Tatsumi M, Groshan K, Blakely RD, Richelson E (December 1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". European Journal of Pharmacology. 340 (2–3): 249–258. doi:10.1016/s0014-2999(97)01393-9. PMID   9537821.
  47. Heffernan GD, Coghlan RD, Manas ES, McDevitt RE, Li Y, Mahaney PE, et al. (November 2009). "Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles". Bioorganic & Medicinal Chemistry. 17 (22): 7802–7815. doi:10.1016/j.bmc.2009.09.023. PMID   19836247.
  48. 1 2 Pälvimäki EP, Roth BL, Majasuo H, Laakso A, Kuoppamäki M, Syvälahti E, Hietala J (August 1996). "Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor". Psychopharmacology. 126 (3): 234–240. doi:10.1007/bf02246453. PMID   8876023. S2CID   24889381.
  49. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M (September 2000). "The interaction of antidepressant drugs with enteric 5-HT7 receptors". Naunyn-Schmiedeberg's Archives of Pharmacology. 362 (3): 284–289. doi:10.1007/s002100000295. PMID   10997731. S2CID   24189673.
  50. 1 2 3 4 5 Richelson E, Nelson A (July 1984). "Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro". The Journal of Pharmacology and Experimental Therapeutics. 230 (1): 94–102. PMID   6086881.
  51. 1 2 3 4 5 6 von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H (January 2009). "Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics". Bioorganic & Medicinal Chemistry Letters. 19 (2): 538–542. doi:10.1016/j.bmcl.2008.09.012. PMID   19091563.
  52. 1 2 3 Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (February 2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn-Schmiedeberg's Archives of Pharmacology. 385 (2): 145–170. doi:10.1007/s00210-011-0704-0. PMID   22033803. S2CID   14274150.
  53. Kanba S, Richelson E (June 1984). "Histamine H1 receptors in human brain labelled with [3H]doxepin". Brain Research. 304 (1): 1–7. doi:10.1016/0006-8993(84)90856-4. PMID   6146381. S2CID   45303586.
  54. El-Fakahany E, Richelson E (January 1983). "Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain". British Journal of Pharmacology. 78 (1): 97–102. doi:10.1111/j.1476-5381.1983.tb17361.x. PMC   2044798 . PMID   6297650.
  55. Peng WH, Lo KL, Lee YH, Hung TH, Lin YC (August 2007). "Berberine produces antidepressant-like effects in the forced swim test and in the tail suspension test in mice". Life Sciences. 81 (11): 933–938. doi:10.1016/j.lfs.2007.08.003. PMID   17804020.
  56. Matthys A, Haegeman G, Van Craenenbroeck K, Vanhoenacker P (June 2011). "Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives". Molecular Neurobiology. 43 (3): 228–253. doi:10.1007/s12035-011-8175-3. PMID   21424680. S2CID   25515856.
  57. Nelson JC (2009). "Tricyclic and Tetracyclic Drugs". In Schatzberg AF, Nemeroff CB (eds.). The American Psychiatric Publishing Textbook of Psychopharmacology. American Psychiatric Pub. pp. 277–. doi:10.1176/appi.books.9781615371624.as09. ISBN   978-1-58562-309-9.
  58. Miyake K, Fukuchi H, Kitaura T, Kimura M, Kimura Y, Nakahara T (December 1991). "Pharmacokinetics of maprotiline and its demethylated metabolite in serum and specific brain regions of rats after acute and chronic administration of maprotiline". Journal of Pharmaceutical Sciences. 80 (12): 1114–8. doi:10.1002/jps.2600801205. PMID   1815068.
  59. 1 2 Vardanyan R, Hruby V (10 March 2006). "Antidepressants". Synthesis of Essential Drugs. Elsevier. pp. 110–. ISBN   978-0-08-046212-7.
  60. 1 2 3 Dawson AH (13 May 1980). "Polycyclic Aromatic Compounds". In Lednicer D, Mitscher LA (eds.). The Organic Chemistry of Drug Synthesis. John Wiley & Sons. pp. 220–. ISBN   978-0-471-04392-8.
  61. 1 2 3 4 Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K (July 2009). "Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters". Chemical Communications (25): 3677–3692. doi:10.1039/b903035m. PMID   19557250.
  62. 1 2 Dart RC (2004). "Chapter 134: Cyclic Antidepressant Drugs". Medical Toxicology. Lippincott Williams & Wilkins. pp. 836–. ISBN   978-0-7817-2845-4.
  63. Morton IK, Hall JM (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 171–. ISBN   978-0-7514-0499-9.
  64. Jensen L. "Drug Shortage Detail: Maprotiline Tablets". www.ashp.org. American Society of Health-System Pharmacists. Retrieved 22 October 2023.